Cargando…

Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease. NAFLD includes a spectrum of hepatic pathologies: simple fatty liver, steatohepatitis and cirrhosis. Insulin resistance may contribute to NAFLD. The liver plays an important role in the production and metabolism of hom...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yanjin, Liu, Jia, Dong, Xuejie, Xu, Yuan, Leng, Song, Wang, Guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103834/
https://www.ncbi.nlm.nih.gov/pubmed/27803497
http://dx.doi.org/10.12659/MSM.897924
_version_ 1782466653952409600
author Hu, Yanjin
Liu, Jia
Dong, Xuejie
Xu, Yuan
Leng, Song
Wang, Guang
author_facet Hu, Yanjin
Liu, Jia
Dong, Xuejie
Xu, Yuan
Leng, Song
Wang, Guang
author_sort Hu, Yanjin
collection PubMed
description BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease. NAFLD includes a spectrum of hepatic pathologies: simple fatty liver, steatohepatitis and cirrhosis. Insulin resistance may contribute to NAFLD. The liver plays an important role in the production and metabolism of homocysteine (HCY), which is known to be an independent risk factor for cardiovascular disease. High HCY level can aggravate NAFLD by increasing the reactive oxygen species and activating oxidative stress. In this study, we investigated the relationship between HCY and NAFLD in euglycemic patients. MATERIAL/METHODS: A total of 1143 euglycemic patients were recruited: 519 patients with non-alcoholic fatty liver disease (NAFLD) and 624 sex and age-matched controls without NAFLD. RESULTS: The NAFLD group had significantly higher HCY level (13.78±5.84 vs. 11.96±3.58 mmol/L, p<0.001), as well as higher body mass index (BMI), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST), fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model assessment for insulin resistance (HOMA-IR), homeostasis model assessment for beta cell function (HOMA-B), and lower high density lipoprotein cholesterol (HDL-C). HCY level was positively correlated with HOMA-IR (r=0.239, p<0.001), TG (r=0.356, p<0.001) and negatively correlated with HDL-C (r=−0.161, p<0.001). In the logistic regression analysis, BMI (beta=0.345, p<0.001), HOMA-IR (beta=0.654, p<0.01), TG (beta=0.881, p<0.001), and HCY (beta=0.04, p=0.044) were the predictors of NAFLD. CONCLUSIONS: Higher HCY level existed in NAFLD patients and was correlated with the severity of insulin resistance. HCY is an independent risk factor for NAFLD.
format Online
Article
Text
id pubmed-5103834
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-51038342016-11-18 Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients Hu, Yanjin Liu, Jia Dong, Xuejie Xu, Yuan Leng, Song Wang, Guang Med Sci Monit Clinical Research BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease. NAFLD includes a spectrum of hepatic pathologies: simple fatty liver, steatohepatitis and cirrhosis. Insulin resistance may contribute to NAFLD. The liver plays an important role in the production and metabolism of homocysteine (HCY), which is known to be an independent risk factor for cardiovascular disease. High HCY level can aggravate NAFLD by increasing the reactive oxygen species and activating oxidative stress. In this study, we investigated the relationship between HCY and NAFLD in euglycemic patients. MATERIAL/METHODS: A total of 1143 euglycemic patients were recruited: 519 patients with non-alcoholic fatty liver disease (NAFLD) and 624 sex and age-matched controls without NAFLD. RESULTS: The NAFLD group had significantly higher HCY level (13.78±5.84 vs. 11.96±3.58 mmol/L, p<0.001), as well as higher body mass index (BMI), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglyceride (TG), glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminase (AST), fasting plasma glucose (FPG), fasting insulin (FINS), homeostasis model assessment for insulin resistance (HOMA-IR), homeostasis model assessment for beta cell function (HOMA-B), and lower high density lipoprotein cholesterol (HDL-C). HCY level was positively correlated with HOMA-IR (r=0.239, p<0.001), TG (r=0.356, p<0.001) and negatively correlated with HDL-C (r=−0.161, p<0.001). In the logistic regression analysis, BMI (beta=0.345, p<0.001), HOMA-IR (beta=0.654, p<0.01), TG (beta=0.881, p<0.001), and HCY (beta=0.04, p=0.044) were the predictors of NAFLD. CONCLUSIONS: Higher HCY level existed in NAFLD patients and was correlated with the severity of insulin resistance. HCY is an independent risk factor for NAFLD. International Scientific Literature, Inc. 2016-11-02 /pmc/articles/PMC5103834/ /pubmed/27803497 http://dx.doi.org/10.12659/MSM.897924 Text en © Med Sci Monit, 2016 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
spellingShingle Clinical Research
Hu, Yanjin
Liu, Jia
Dong, Xuejie
Xu, Yuan
Leng, Song
Wang, Guang
Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title_full Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title_fullStr Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title_full_unstemmed Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title_short Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients
title_sort clinical study of serum homocysteine and non-alcoholic fatty liver disease in euglycemic patients
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5103834/
https://www.ncbi.nlm.nih.gov/pubmed/27803497
http://dx.doi.org/10.12659/MSM.897924
work_keys_str_mv AT huyanjin clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients
AT liujia clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients
AT dongxuejie clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients
AT xuyuan clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients
AT lengsong clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients
AT wangguang clinicalstudyofserumhomocysteineandnonalcoholicfattyliverdiseaseineuglycemicpatients